TY - JOUR
T1 - Testing of a bioactive, moldable bone graft substitute in an infected, critically sized segmental defect model
AU - Brown, Matt E.
AU - Zou, Yuan
AU - Peyyala, Rebecca
AU - Huja, Sarandeep S.
AU - Cunningham, Larry L.
AU - Milbrandt, Todd A.
AU - Dziubla, Thomas D.
AU - Puleo, David A.
N1 - Publisher Copyright:
© 2017 Wiley Periodicals, Inc.
PY - 2018/7
Y1 - 2018/7
N2 - Large infected bone defects, often resulting from high energy traumas, are difficult to treat due to their variability in complexity and location. Standard treatment for infected bone defects begins with a protocol that includes a series of debridements in conjunction with an extended course of systemic antibiotics. Only after the infection has been eliminated will repair of the defect commence, typically with implantation of autologous bone. To address some of the shortcomings of the standard treatment methods, such as serial procedures, limited grafting material, and the need for a second surgical site for autologous bone, a sequential, dual drug-releasing, moldable, calcium sulfate-based bone graft substitute was developed previously. In the present studies, the effectiveness of the material for treating both the infection with vancomycin and bone defect with simvastatin was evaluated in vivo using a critically sized, infected segmental defect model in rat femurs. Although the infection was not fully eliminated, the local release of vancomycin increased survivorship of infected animals by 464% compared to nontreated controls. Infected animals receiving antimicrobial treatment showed comparable amounts of new bone formation within the defect site when compared to noninfected controls. Incorporating agents capable of disrupting established biofilms into bone graft substitutes may enhance effectiveness in treating a biofilm infection within a bone defect.
AB - Large infected bone defects, often resulting from high energy traumas, are difficult to treat due to their variability in complexity and location. Standard treatment for infected bone defects begins with a protocol that includes a series of debridements in conjunction with an extended course of systemic antibiotics. Only after the infection has been eliminated will repair of the defect commence, typically with implantation of autologous bone. To address some of the shortcomings of the standard treatment methods, such as serial procedures, limited grafting material, and the need for a second surgical site for autologous bone, a sequential, dual drug-releasing, moldable, calcium sulfate-based bone graft substitute was developed previously. In the present studies, the effectiveness of the material for treating both the infection with vancomycin and bone defect with simvastatin was evaluated in vivo using a critically sized, infected segmental defect model in rat femurs. Although the infection was not fully eliminated, the local release of vancomycin increased survivorship of infected animals by 464% compared to nontreated controls. Infected animals receiving antimicrobial treatment showed comparable amounts of new bone formation within the defect site when compared to noninfected controls. Incorporating agents capable of disrupting established biofilms into bone graft substitutes may enhance effectiveness in treating a biofilm infection within a bone defect.
KW - bone graft substitute
KW - calcium sulfate
KW - infection
KW - simvastatin
KW - vancomycin
UR - http://www.scopus.com/inward/record.url?scp=85030171231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030171231&partnerID=8YFLogxK
U2 - 10.1002/jbm.b.34001
DO - 10.1002/jbm.b.34001
M3 - Article
C2 - 28926192
AN - SCOPUS:85030171231
SN - 1552-4973
VL - 106
SP - 1878
EP - 1886
JO - Journal of Biomedical Materials Research - Part B Applied Biomaterials
JF - Journal of Biomedical Materials Research - Part B Applied Biomaterials
IS - 5
ER -